April 13, 2024

03/29/2024 | NYSE:LH | Press release

Expanded partnership to help increase patient access to critical genetic screening services, including genetic counseling and test result turnaround time

HOUSTON, March 29, 2024 /PRNewswire/ — The Prelude Network&circulatedR; (Prelude), the largest network of fertility clinics in North Americatoday announced an expansion of its partnership with Labcorp (NYSE: LH), a global leader in innovative biopharmaceutical laboratory and diagnostic services, to serve as its Preferred Genetic Carrier Screening Laboratory.

Labcorp partners with Prelude and its extensive network of more than 90 clinics across the U.S. and parts of Canada, providing FDA-approved clinical laboratories and donor testing at each clinic. The expansion of this partnership provides another level of genetic carrier screening services to Prelude patients, including in-office phlebotomists and patient care centers. Additionally, Labcorp offers comprehensive genetic counseling, provider inquiry services, and free review of carrier screening results for patients. It also leverages a pre-existing interface with electronic medical records to request and report carrier screening results, greater reporting clarity with variant-specific interpretation, and highly competitive network contract rates to other genetic tests. To improve financial access to genetic carrier screening for the US patient population, Labcorp contracts with many insurance companies.

“Genetic screening is a vital part of fertility diagnosis as it helps patients and doctors make critical decisions about care and treatment options that lead to optimal results,” said TJ Farnsworth, founder and CEO of Inception Fertility, the parent company of The Prelude Network. “By expanding our partnership with Labcorp, we can provide a higher level of care to patients who require genetic screening services to build their families, and we are excited to work closely with Labcorp to improve the accessibility and experience of patient. “

This expanded partnership also supports Prelude’s Center of Genetic Excellence program and its commitment to providing best-in-class services to patients who incorporate genetic testing as part of their care plans. Launched in 2022, one of the Genetic Excellence Center’s initiatives is to establish standardized, high-quality genetic screening for patients and egg donors in the Prelude network.

“Prelude is excited to offer our patients greater access to best-in-class genetic carrier screening,” he says. Laura Black, Certified Genetic Counselor and Director of Genetic Services at Inception. “We believe that by naming Labcorp as The Prelude Network’s Preferred Genetic Carrier Screening Laboratory, we can expand our efforts to give every aspiring parent a greater chance of bringing home a healthy baby.”

To learn more about Prelude clinics, which span the U.S. and part of Canadavisit preludefertility.com.

About the Prelude network&circulatedR;

The Prelude Network&circulatedR; (Prelude), the fastest growing network of fertility clinics and the largest provider of comprehensive fertility services in North Americais the Inception Fertility clinical network – a family of fertility brands covering every part of the fertility journey, from diagnosis and treatment to affordability.

Each clinic, as part of Prelude, is committed to providing the highest level of personalized fertility care by the nation’s leading endocrinologists, embryologists and reproductive professionals, focusing on excellence in science, medicine and the patient experience. The growing Prelude Network has more than 90 locations nationwide, offering a wide range of fertility services, including egg freezing, IVF, genetic testing, LGBTQ+ fertility options, and egg/embryo storage, among others.

Prelude clinics include Aspire Fertility Austin (Texas); Aspire Fertility Dallas (Texas); Aspirate Fertility McAllen (Texas); Aspire Fertility San Antonio (Texas); Aspire Houston Fertility Institute (Texas); Advanced Fertility Center Chicago (Illinois); Center for Reproductive Medicine (Florida); Indiana Fertility Institute (Indiana); IVFMD (Florida); Mainline Fertility (Pennsylvania); NYU Langone Fertility Center (new York); NYU Langone RSNY (new York); Pacific center for Reproductive Medicine (Canada); Pacific Fertility Center (California); Regional Fertility Program (Canada); Reproductive Biology Associates (Georgia); Tennessee Fertility Institute (Tennessee) and Reproductive Medicine Group (Florida).

About early fertility

Early fertility (Inception) is a family of fertility brands committed to helping patients build their own families. Built by patients for patients, Inception’s goal is to achieve the highest standard in expertise, science and medicine in an effort to enhance each patient’s experience and achieve better outcomes.

Inception’s medical experts are pioneers in fertility treatment. Our doctors are some of the first to use revolutionary assisted reproductive technologies (ART) – including in vitro fertilization (IVF), preimplantation genetic testing (PGT), and fertility preservation services – and continue to lead the industry by leveraging these technologies through development, research and thought leadership.

Through its growing family of national organizations – which includes The Prelude Network&circulatedR;, the fastest-growing network of fertility clinics and the largest provider of comprehensive fertility services in North America; Pathways Fertility, clinics that offer affordable, individualized and high-quality care; MyEggBank&circulatedR;, one of the largest frozen donor egg banks in North America; BUNDL Fertility, a multi-cycle fertility services cluster program; HavenCryoprovider of long-term reproductive preservation and storage solutions and NutraBloom&circulatedR;a premium lifestyle brand with expertly formulated supplements to support individuals’ preconception health and wellness goals – Inception is working to deliver on its promise to go beyond what is possible to exceed consumers’ expectations. patients.

About Labcorp

Labcorp (NYSE: LH) is a global leader in innovative, comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear, confident decisions. We provide insights and scientific advances to improve health and improve lives through our unmatched diagnostics and drug development laboratory capabilities. The company’s more than 67,000 employees serve customers in more than 100 countries, have worked on more than 84% of new drugs approved by the FDA in 2023, and have performed more than 600 million tests on patients worldwide. Learn more about us at www.labcorp.com.

Media Contact:

Mia Humphreys

239-297-6592

MHumphreys@kruppagency.com

Spin-off View original content to download multimedia: https://www.prnewswire.com/news-releases/the-prelude-network-names-labcorp-its-preferred-genetic-carrier-screening-lab-302103351.html

SOURCE The Prelude Network

Leave a Reply

Your email address will not be published. Required fields are marked *